DMPK
Clinically Relevant Drug Transporters: Understanding DDI with a View to Better Prediction and Control
December 15 by Andrea CharlesHow is the industry seeking to understanding DDI with a view to better prediction and control? How has the current technology landscape changed following the publication of the ITC white paper?...
Challenges and Benefits of Patient-Based Phase I Trials
May 05 by Pharma IQPharma IQ held a Q&A session with Dr. James Dow, Director of Clinical Pharmacology & DMPK, (OSI) Prosidion to gain a few insights into phase I clinical development and patient-bas...
Fail Early in Clinical Development if You Want to Succeed
June 10 by Andrea CharlesIf you are going to fail, it is better to fail earlier. All phases of clinical research are striving to reduce attrition, streamline their processes and develop drugs cost-effectively.
Novartis & Lundbeck: Significance of Drug Transporters Now and in the Future
April 24 by Pharma IQThe Clinically Relevant Drug Transporters Conference has been a major DMPK meeting point in Europe for 5 years now. In preparation for this year’s 5th annual meeting in Berlin, we asked Dr. La...